NCT06863233View on ClinicalTrials.gov

A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

March 3, 2025

Primary Completion Date

March 3, 2028

Study Completion Date

March 3, 2028

Conditions
Lung CancerNon Small Cell Lung CancerMetastatic Non Small Cell Lung Cancer
Interventions
DRUG

Zirconium Zr 89 crefmirlimab berdoxam

Zirconium Zr 89 crefmirlimab berdoxam, the investigational agent proposed in this imaging study, is an anti-CD8 minibody (crefmirlimab), conjugated with deferoxamine (Df, berdoxam) and radiolabeled with Zirconium-89.

DIAGNOSTIC_TEST

PET/CT Scan

Each patient will undergo up to four infusions of Zirconium Zr 89 crefmirlimab berdoxam followed by PET/CT 24 hours later (+/- 3 hours).

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All protocol activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Consent only), Harrison

11553

RECRUITING

Memorial Sloan Kettering Cancer Center @ Nassau (Consent only), Uniondale

11725

RECRUITING

Memorial Sloan Kettering Cancer Center @ Suffolk-Commack (Consent only), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (Consent Only), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (Consent Only), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (Consent Only), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER